Setback for an Alzheimer's disease vaccine lessons learned

Neurology

Volumn 61, Issue 1, 2003, Pages 7-8

  Mathews, Paul M ^a,b   Nixon, Ralph A ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFECT; EDITORIAL; HUMAN; IMMUNOTHERAPY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0038692030     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.61.1.7     Document Type: Editorial

References (15)

1. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985;82:4245-4249.
2. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-890.
3. Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 1998;21:479-505.
4. Orgogozo J-M, Gilman S, Dartigues J-F, et al. Subacute meningoen-cephalitis in a subset of patients with AD after Aβ immunization. Neurology 2003;61:46-54.
5. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
6. Janus C, Pearson J, McLaurin J, et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-982.
7. Morgan D, Diamond DM, Gottschall PE, et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-985.
8. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-919.
9. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-8855.
10. Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 2002;298:1379.
11. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003;9:448-452.
12. McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002;8:1263-1269.
13. Matsuoka Y, Saito M, LaFrancois J, et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid. J Neurosci 2003;23:29-33.
14. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
15. Hock C, Konietzko U, Streffer JR, et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38:547-554.